|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-2-11
|
|
pubmed:abstractText |
In the Phase III ARTEMIS Trial, treatment-naive patients received once-daily darunavir/ritonavir (DRV/r) 800/100 mg (n = 343) or lopinavir/ritonavir (LPV/r) 800/200 mg (total daily dose; n = 346) plus fixed-dose tenofovir disoproxil fumarate/emtricitabine. The primary outcome measure was non-inferiority of DRV/r versus LPV/r (HIV type-1 [HIV-1] RNA<50 copies/ml). Here, a detailed 96-week resistance analysis is presented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenine,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Lopinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/darunavir,
http://linkedlifedata.com/resource/pubmed/chemical/emtricitabine,
http://linkedlifedata.com/resource/pubmed/chemical/tenofovir disoproxil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
2040-2058
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
99-108
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21311113-Adenine,
pubmed-meshheading:21311113-Adult,
pubmed-meshheading:21311113-Anti-HIV Agents,
pubmed-meshheading:21311113-Deoxycytidine,
pubmed-meshheading:21311113-Drug Administration Schedule,
pubmed-meshheading:21311113-Drug Resistance, Viral,
pubmed-meshheading:21311113-Drug Therapy, Combination,
pubmed-meshheading:21311113-Female,
pubmed-meshheading:21311113-Genetic Association Studies,
pubmed-meshheading:21311113-HIV Infections,
pubmed-meshheading:21311113-HIV-1,
pubmed-meshheading:21311113-Humans,
pubmed-meshheading:21311113-Lopinavir,
pubmed-meshheading:21311113-Male,
pubmed-meshheading:21311113-Mutation,
pubmed-meshheading:21311113-Phosphonic Acids,
pubmed-meshheading:21311113-Polymorphism, Genetic,
pubmed-meshheading:21311113-Pyrimidinones,
pubmed-meshheading:21311113-RNA, Viral,
pubmed-meshheading:21311113-Ritonavir,
pubmed-meshheading:21311113-Sulfonamides,
pubmed-meshheading:21311113-Treatment Failure,
pubmed-meshheading:21311113-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
|
|
pubmed:affiliation |
Tibotec BVBA, Beerse, Belgium. elathouw@its.jnj.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
